Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Aardvark Therapeutics, Inc. Common Stock (AARD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AARD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 13.83% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 284.41M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 4.88 - 19.58 | Updated Date 05/31/2025 |
52 Weeks Range 4.88 - 19.58 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 202920214 | Price to Sales(TTM) - |
Enterprise Value 202920214 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21384400 | Shares Floating 18389495 |
Shares Outstanding 21384400 | Shares Floating 18389495 | ||
Percent Insiders 24.03 | Percent Institutions 24.9 |
Upturn AI SWOT
Aardvark Therapeutics, Inc. Common Stock
Company Overview
History and Background
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of metabolic diseases, including obesity and non-alcoholic steatohepatitis (NASH). It was founded in 2017 and is headquartered in Solana Beach, California. The company is still relatively young and focuses on developing its lead compounds through clinical trials.
Core Business Areas
- Drug Development: Aardvark focuses on developing and commercializing innovative drugs for the treatment of metabolic diseases. Their main focus is on the development of TERN-101, a farnesoid X receptor (FXR) agonist, for the treatment of NASH and obesity.
Leadership and Structure
Dr. Stephen A. Farr is the current CEO of Aardvark Therapeutics. As a clinical-stage company, the organizational structure emphasizes research, development, and clinical trial management. The board of directors oversees the company's strategy and operations.
Top Products and Market Share
Key Offerings
- TERN-101: TERN-101 is Aardvark's lead drug candidate, an oral FXR agonist. It is in clinical development for NASH and obesity. Market share data is not currently available as the drug is not yet approved. Key competitors in the NASH market include Madrigal Pharmaceuticals (resmetirom), Viking Therapeutics (VK2809), and Akero Therapeutics (efruxifermin). The obesity market has existing solutions like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. The metabolic disease market, including NASH and obesity, is rapidly growing due to the increasing prevalence of these conditions worldwide. There is significant unmet medical need, and the market is attracting considerable investment and competition.
Positioning
Aardvark Therapeutics is positioned as a clinical-stage company focused on developing innovative therapies for metabolic diseases. Its competitive advantage lies in its FXR agonist program and its potential to provide a differentiated treatment option.
Total Addressable Market (TAM)
The TAM for NASH is projected to be in the tens of billions of dollars annually. The TAM for Obesity is projected to be much larger. Aardvark is positioned to capture a portion of this market if its drug candidate proves successful in clinical trials and receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel FXR agonist program
- Experienced management team
- Focused on a high-growth market
Weaknesses
- Limited financial resources
- Reliance on a single drug candidate
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure to secure funding
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Aardvark Therapeutics faces competition from established pharmaceutical companies and other biotech firms developing therapies for metabolic diseases. Its competitive advantage lies in its FXR agonist program and its potential to provide a differentiated treatment option.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the progression of its clinical trials and financing activities. As a young company, revenue growth is not yet a primary indicator.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates vary, but positive clinical trial results would likely lead to increased projections.
Recent Initiatives: Recent initiatives include the advancement of TERN-101 through clinical trials, securing additional funding, and exploring potential partnerships.
Summary
Aardvark Therapeutics is a clinical-stage biopharmaceutical company with a focus on metabolic diseases. Its lead drug candidate, TERN-101, is being developed for NASH and obesity. The company's success depends on positive clinical trial results and its ability to secure funding. It faces competition from larger, more established pharmaceutical companies, but its novel FXR agonist program provides a potential competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biopharmaceutical companies involves significant risks, including clinical trial failure and regulatory setbacks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aardvark Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2025-02-13 | CEO, Secretary & Director Dr. Tien-Li Lee M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://aardvarktherapeutics.com |
Full time employees 26 | Website https://aardvarktherapeutics.com | ||
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.